Core Viewpoint - Aoyi Technology, a leading developer in dexterous hands and neural interfaces, has successfully completed a nearly 100 million yuan B++ round of financing, aimed at accelerating R&D breakthroughs in dexterous hand technology and enhancing global market presence [1][4]. Group 1: Financing and Growth Strategy - Aoyi Technology completed a nearly 100 million yuan B++ round of financing, with investments from Infiniti Capital, Zhejiang State-owned Capital Operation Co., and Womeda Capital [1]. - The financing will be used to accelerate the R&D of dexterous hand technology, promote the launch of new dexterous hand products, and enhance the production capacity by 100% [1][4]. - The company aims to establish an internationally leading standardized production system and optimize production processes [1]. Group 2: Product Development and Market Position - Aoyi Technology has developed multiple innovative products that combine advanced technology with commercial viability, gaining wide recognition in the global market [1][8]. - The first dexterous hand product has received positive feedback from multiple clients in the embodied robotics sector, highlighting its importance as a key solution in the industry [2][4]. - The company has successfully integrated neural interfaces into various applications, including smart prosthetic hands for amputees and exoskeleton robots for individuals with hand function disabilities [4]. Group 3: Technological Advancements - Aoyi Technology has over 80 patents related to its self-developed brain/muscle interface technology, which supports its medical-grade neural interaction platform [8]. - The OHand™ series of smart bionic hands has rapidly captured market share since its launch in 2020, achieving FDA/CE certifications and expanding into international markets [8]. - The upcoming ROH-AP001 dexterous hand is expected to feature tactile and pressure sensing capabilities, set to launch soon [5].